Video Experimental Relacionado
Updated: Feb 24, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Factores de riesgo de trombosis venosa profunda en la hemorragia intracerebral espontánea y sus implicaciones
Xianju Liang1,2, Chuyue Wu1,2,3, Yu Huang1,2
1Department of Neurology, Chongqing University Three Gorges Hospital, Chongqing, China.
Objectives:
This study sought to identify the risk factors associated with venous thrombosis for spontaneous intracerebral hemorrhage (ICH) in a long term.
Methods:
A retrospective analysis was performed on the ICH patients between January 2021 and December 2022.
Results:
A total of 737 patients were examined with 86 patients (11.7 %) of venous thrombosis. The risk factors linked to venous thrombosis were the length of hospital stay (p<0.001), admission NIH Stroke Scale (p=0.008), and D-dimer levels (p=0.041). No significant differences in mortality rates existed at any timepoint in this study between patients with and without venous thrombosis after correction analysis (p>0.05). However, patients who developed a venous thrombosis exhibited a higher rate of poor outcomes compared to patients who did not develop a venous thrombosis (p<0.05) at the time of hospital discharge (90.7 % vs. 59.6 %), 90 days post-onset (73.2 % vs. 41.6 %), and 1-year post-onset (73.2 % vs. 41.0 %).
Conclusions:
The identified risk factors for venous thrombosis among ICH patients include extended hospitalization, elevated NIH Stroke Scale score and D-dimer level. The occurrence of a venous thrombosis correlated with inferior functional outcomes at the time of hospital discharge, at 90 days and 1 year after onset.
Más Videos Relacionados
Videos de Conceptos Relacionados
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins

